Clinical trial
Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal…
NCT00327119 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00327119 |
|---|---|
| Title | Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer |
| Official title | A Phase 2 Multicenter Single Arm Clinical Trial of ABX EGF (Panitumumab) Monotherapy in Japanese Subjects With Metastatic Colorectal Cancer Who Developed Progressive Disease or Relapsed While on or After Prior Fluoropyrimidine, Irinotecan and Oxaliplatin Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | ABX-EGF (panitumumab) |
| Enrollment | 50 |
| Start date | Apr 1, 2006 |
| First posted | May 18, 2006 |
| Last update posted | Sep 14, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: